Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Interest & Investment Income for 13 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 14.62% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.4 million, a 19.91% decrease, with the full-year FY2025 number at $37.4 million, down 19.91% from a year prior.
  • Interest & Investment Income was $9.5 million for Q4 2025 at Madrigal Pharmaceuticals, down from $10.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $14.2 million in Q2 2024 to a low of $52000.0 in Q4 2021.
  • A 5-year average of $5.3 million and a median of $3.7 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: tumbled 92.71% in 2021, then soared 5372.46% in 2023.
  • Madrigal Pharmaceuticals' Interest & Investment Income stood at $52000.0 in 2021, then soared by 1969.23% to $1.1 million in 2022, then surged by 732.06% to $9.0 million in 2023, then rose by 23.75% to $11.1 million in 2024, then decreased by 14.62% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Interest & Investment Income are $9.5 million (Q4 2025), $10.3 million (Q3 2025), and $8.2 million (Q2 2025).